GenMark’s ePlex® Blood Culture Identification (BCID) Panels provide the broadest coverage of organisms that can lead to sepsis along with their resistance genes. The ePlex BCID Panels also include several contamination rule-out targets which are intended to help de-escalate unnecessary antibiotics. When combined with ePlex connectivity solutions, the ePlex BCID Panels are designed to help accelerate the delivery and interpretation of their test results. The ePlex BCID Panels are truly the only test for rapid, routine blood culture identification.
It is estimated that 20-30% of patients receive ineffective initial antibiotic therapy and the mortality rate for these patients increases up to 7.6% for every hour effective antibiotics are delayed.
The ePlex BCID Panels aid clinicians in the identification of bacterial and fungal organisms as well as antibiotic resistance genes within approximately 1.5 hours of blood bottle positivity, allowing treatment decisions to occur days earlier than with conventional methods. Unique ePlex solutions, like the ePlex Templated Comments Module, help to improve antimicrobial stewardship and optimize patient care.
The ePlex BCID Panels offer the broadest coverage of organisms and resistance markers that can lead to sepsis, including anaerobes and multidrug resistant organisms (MDRO), as well as common and emerging fungal pathogens. The ePlex BCID Fungal Pathogen (FP) Panel* is the only multiplex molecular panel to include Candida auris, an MDRO of increasing prevalence.
|Blood Culture Identification Test||Inclusivity based on Potula et al.||Inclusivity based on GenMark Clinical Study Database|
|ePlex BCID (GP, GN and FP) Panels||99.6%||94.0%|
Blood culture panel target inclusivity based on prevalence of organisms that cause blood stream infections in the United States (Potula et. al at Temple University Hospital, n = 2,569)2 and GenMark’s prospective clinical trial database (n=1111 from 10 US clinical study sites).
The ePlex BCID Panels include 4 gram-positive and 10 gram-negative resistance genes that can be detected days earlier than conventional antimicrobial susceptibility tests (AST), enabling earlier escalation of therapy for resistant organisms or de-escalation of empirical antimicrobials. Rapid detection of antibiotic resistance genes when applied with local epidemiology of resistance, has been shown to agree 100% with subsequent phenotypic susceptibility testing, allowing for recommendation of a targeted therapy earlier.
Published studies show that up to 30% of positive blood cultures may be due to contaminants which can result in continuation of unnecessary antibiotics. ePlex BCID Panels are designed to allow labs to more rapidly differentiate a contaminant from a true infection, enabling rapid de-escalation and discharge of patients with a bloodstream infection 2-3 days earlier than conventional methods.
|ePlex BCID-GP Panel||ePlex BCID-GN* Panel||ePlex BCID-FP* Panel|
|Gram-Positive Organisms||Gram-Negative Organisms||Fungal Organisms|
|Bacillus cereus group||Acinetobacter baumannii||Candida albicans|
|Bacillus subtilis group||Bacteroides fragilis||Candida auris|
|Cutibacterium acnes (Propionibacterium acnes)||Cronobacter sakazakii||Candida famata|
|Enterococcus||Enterobacter (non-cloacae complex)||Candida glabrata|
|Enterococcus faecalis||Enterobacter cloacae complex||Candida guilliermondii|
|Enterococcus faecium||Escherichia coli||Candida kefyr|
|Lactobacillus||Fusobacterium nucleatum||Candida krusei|
|Listeria||Fusobacterium necrophorum||Candida lusitaniae|
|Listeria monocytogenes||Haemophilus influenzae||Candida parapsilosis|
|Micrococcus||Klebsiella oxytoca||Candida tropicalis|
|Staphylococcus||Klebsiella pneumoniae||Cryptococcus gattii|
|Staphylococcus aureus||Morganella morganii||Cryptococcus neoformans|
|Staphylococcus epidermidis||Neisseria meningitides||Fusarium|
|Streptococcus agalactiae group||Salmonella|
|Streptococcus pyogenes (GAS)||Serratia marcescens|
|Resistance Genes||Resistance Genes|
|Pan Targets||Pan Targets|
|Pan Gram-Negative||Pan Gram-Positive|
|Pan Candida||Pan Candida|
“Delivering definitive identification with resistance markers can aid the clinician’s decision on more targeted antimicrobial therapy sooner than conventional methods.” – Maria Malloy, Surveillance Scientist, National HCAI and AMR Response Team, Galway University Hospital, Ireland
“ePlex Panels have significantly changed the way we deal with blood cultures. The medical laboratory scientists are happy with its ease of use and hands-on time per test, and we can provide clinicians more detailed information much sooner – within a couple hours of a positive blood culture, rather than days.”
Dr. Cathal Collins, Cavan General Hospital, Ireland
To learn more about the Blood Culture Identification (BCID) Panels or to schedule a demonstration, contact us at 1.800.373.6767 or email us.
The ePlex BCID-GN and BCID-FP Panels are not available for sale in the United States
 IDSA: Better Tests Better Care, The Promise of Next Generation Diagnostics.
 Kumar, et al. (2006) Crit Care Med. 34 (6):1589-1596
 Singh, N. (2001) Clin Infect Dis, 33(10):1692-1696
 Detection rate based on panel inclusivity only, not a sensitivity/performance claim
 Rödel, et. al. (2016), Diag Micro and Inf Dis, 84:252-257
 Murray, P. et. al. (2012), Crit Care Med,Current Approaches to the Diagnosis of Bacterial and Fungal Bloodstream Infections for the ICU.